Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| FitBiomics, Inc. | INDUSTRY |
Not provided
Not provided
Not provided
Not provided
Monocentric Crossover Study to Assess the Tolerability and the Efficacy of a Mix of Probiotic Strains Doses vs Placebo in Athletes Performance
This study will intend:
- To assess the tolerability and the efficacy of a food supplements into improving performance in a panel of athletes after repeated use for 4 consecutive weeks, under the normal conditions of use, compared to a placebo.
The present study aimed at assessing the tolerability and the efficacy of a food supplements probiotics-based (L. acidophilus FB0012, L. plantarum FB0015, and L. rhamnosus FB0047 encapsulated in acid-resistant capsules) into improving performance in a panel of athletes after repeated use for 4 consecutive weeks, under the normal conditions of use, compared to a placebo.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Active | Active Comparator | Probiotic capsule (composition same as described above - L. acidophilus FB0012, L. plantarum FB0015, and L. rhamnosus FB0047 encapsulated in acid-resistant capsules alongside additional potato starch as a filler). |
|
| Placebo | Placebo Comparator | Placebo capsule (placebo consisted of the same capsules filled with potato starch) |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Probiotic capsule | Dietary Supplement | probiotic capsule (composition same as described above - L. acidophilus FB0012, L. plantarum FB0015, and L. rhamnosus FB0047 encapsulated in acid-resistant capsules |
| Measure | Description | Time Frame |
|---|---|---|
| Evaluation of physical parameters: soreness | Change of Soreness (measured by a 5-point scale) between T1 and T2 | at T1 (12 weeks with placebo) and T1 (12 week with ACTIVE) |
| Evaluation of physical parameters: fatigue | Change of Fatigue (measured by a 5-point scale) between T1 and T2 | at T1 (12 weeks with placebo) and T1 (12 week with ACTIVE) |
| Evaluation of physical parameters: energy | Change of Energy (measured by a 5-point scale) between T1 and T2between T1 and T2 | at T1 (12 weeks with placebo) and T1 (12 week with ACTIVE) |
| Evaluation of physical parameters:Sleep quality | Change of Sleep quality (evaluated by Sleep Quality Scale (SQS)) between T1 and T2between T1 and T2 | at T1 (12 weeks with placebo) and T1 (12 week with ACTIVE) |
| Evaluation of physical parameters:Digestive symptoms | Change of the frequency of four individual digestive symptoms (abdominal pain/discomfort, bloating, flatulence/passage of gas and borborygmi/rumbling stomach) will be evaluated with five-point Likert scales that range from 0 (never) to 4 (every day of the week), between T1 and T2 | at T1 (12 weeks with placebo) and T1 (12 week with ACTIVE) |
| Gut microbiota analysis ON FECAL SAMPLE by mean of 16S and metagenomic shotgun sequencing | 16S and metagenomic shotgun sequencing | at baseline (T0) |
| Gut microbiota analysis ON FECAL SAMPLE by mean of 16S and metagenomic shotgun sequencing |
Not provided
Not provided
Inclusion Criteria:
Exclusion Criteria:
1. Known sensitivity to any compound of the Investigational product. 2. Pregnant or breast feeding females or planning a pregnancy. 3. Serious intercurrent infection or other active disease up to three months prior to study entry.
4. History of concurrent malignancy. 5. History of significant alcohol or drug abuse. 6. Significant psycho-social or psychiatric disorders that may impair the subject's ability to meet the study requirements.
7. Significant concurrent medical disorders that may impair the subject's ability to participate over the whole one year of the study.
8. Any other medical condition which in the Investigator's opinion would prevent the subject from participating in the study.
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| DANIELA PINTO | Giuliani S.p.A | Study Chair |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Centro Sportivo Parma Football | Collecchio | Parma | 43044 | Italy |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Type | Includes Protocol | Includes SAP | Includes ICF | Document Label | Document Date | Document Uploaded Date | Document File Name |
|---|---|---|---|---|---|---|---|
| ICF | No | No | Yes | Informed Consent Form | Mar 11, 2020 | Oct 16, 2023 | ICF_000.pdf |
Not provided
| ID | Term |
|---|---|
| D019936 | Probiotics |
| ID | Term |
|---|---|
| D019587 | Dietary Supplements |
| D005502 | Food |
| D000066888 | Diet, Food, and Nutrition |
| D010829 | Physiological Phenomena |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
|
| Placebo | Dietary Supplement | placebo consisted of the same capsules filled with potato starch |
|
16S and metagenomic shotgun sequencing |
| at T1 (12 weeks with placebo) a |
| Gut microbiota analysis ON FECAL SAMPLE by mean of 16S and metagenomic shotgun sequencing | 16S and metagenomic shotgun sequencing | at T1 (12 week with ACTIVE) |
| Microbial dysbiosis ON URINE SAMPLES by mean of liquid chromatography- surface-activated chemical-ionization-electrospray ionization (LC/SASI-MS) and tandem mass spectrometry (MS/MS) | By mean of liquid chromatography bacteria that potentially could cause dysbiosis by analyzing the profile of urine's metabolites and combining the results in the SANIST platform which predicts the intestinal dysbiosis based on the antagonist and pathogen bacteria pharmacological activity | at baseline (T0), |
| Microbial dysbiosis ON URINE SAMPLES by mean of liquid chromatography- surface-activated chemical-ionization-electrospray ionization (LC/SASI-MS) and tandem mass spectrometry (MS/MS) | By mean of liquid chromatography bacteria that potentially could cause dysbiosis by analyzing the profile of urine's metabolites and combining the results in the SANIST platform which predicts the intestinal dysbiosis based on the antagonist and pathogen bacteria pharmacological activity | at T1 (12 weeks with placebo) |
| Microbial dysbiosis ON URINE SAMPLES by mean of liquid chromatography- surface-activated chemical-ionization-electrospray ionization (LC/SASI-MS) and tandem mass spectrometry (MS/MS) | By mean of liquid chromatography bacteria that potentially could cause dysbiosis by analyzing the profile of urine's metabolites and combining the results in the SANIST platform which predicts the intestinal dysbiosis based on the antagonist and pathogen bacteria pharmacological activity | T1 (12 week with ACTIVE) |
| D019602 |
| Food and Beverages |